Kyntra Bio (NASDAQ: KYNB) announced that data from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE